,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-05-09,XOMA Corporation 's ( XOMA ) shares declined 18.5% after the company reported wider-than-expected loss per share in the first quarter of 2014 and slower-than-expected patient enrolment in two phase III studies being conducted with gevokizumab.,0.01786900870501995,0.9722651839256287,0.00986574962735176,negative,-0.9543961882591248
1,2014-05-09,"The company posted a loss of 23 cents per share, wider than the Zacks Consensus Estimate of a loss of 19 cents per share and the year-ago loss of 15 cents per share.",0.0259303767234087,0.9617275595664978,0.012342085130512714,negative,-0.9357971549034119
2,2014-05-09,"Total revenues for the reported quarter were $3.4 million, down 63.9% from the year-ago quarter.",0.018225660547614098,0.9728513360023499,0.008923043496906757,negative,-0.95462566614151
3,2014-05-09,Revenues were lower than the year-ago quarter primarily due to a milestone payment from Servier.,0.017354920506477356,0.9688770174980164,0.013768062926828861,negative,-0.9515221118927002
4,2014-05-09,Revenues were well below the Zacks Consensus Estimate of $9 million.,0.022718043997883797,0.9061480760574341,0.07113385945558548,negative,-0.883430004119873
5,2014-05-09,R&D expenses for the quarter increased 29.5% to $21.5 million.,0.9513612389564514,0.02334747463464737,0.02529124729335308,positive,0.9280137419700623
6,2014-05-09,"The surge was driven by increased costs related to pipeline development, including gevokizumab and higher stock-based compensation expense.",0.9304668307304382,0.039608463644981384,0.029924727976322174,positive,0.8908583521842957
7,2014-05-09,XOMA is working on commencing a phase III study on gevokizumab for inflammatory pyoderma gangrenosum (PG).,0.34767529368400574,0.0086796460673213,0.6436450481414795,neutral,0.33899563550949097
8,2014-05-09,XOMA intends to submit the phase III study protocols for gevokizumab to the U.S. Food and Drug Administration (FDA) within the next few weeks.,0.08465835452079773,0.006280497647821903,0.9090611338615417,neutral,0.0783778578042984
9,2014-05-09,A response from the FDA should be out by Aug 2014.,0.07227563112974167,0.015606717206537724,0.912117600440979,neutral,0.05666891485452652
10,2014-05-09,Gevokizumab received orphan drug status in the U.S. for the treatment of PG.,0.7948406934738159,0.013645387254655361,0.19151392579078674,positive,0.7811952829360962
11,2014-05-09,"Meanwhile, partner Servier is enrolling patients in the phase III EYEGUARD program on gevokizumab.",0.5601003766059875,0.009645279496908188,0.43025434017181396,positive,0.5504550933837891
12,2014-05-09,"EYEGUARD-A is being conducted to evaluate gevokizumab for the treatment of non-infectious uveitis (NIU), EYEGUARD-B is evaluating gevokizumab's ability to prevent disease flares in patients with Behçet's uveitis and EYEGUARD-C is being conducted to evaluate gevokizumab for the prevention of disease flares in NIU patients who are controlled with steroids.",0.08613645285367966,0.008270894177258015,0.905592679977417,neutral,0.07786555588245392
13,2014-05-09,Gevokizumab has orphan drug status for NIU and Behçet's uveitis.,0.0996803417801857,0.03877696767449379,0.8615427017211914,neutral,0.06090337410569191
14,2014-05-09,"However, patient enrolment for EYEGUARD-A and EYEGUARD-C is going slower than expected.",0.018096888437867165,0.962986946105957,0.018916107714176178,negative,-0.9448900818824768
15,2014-05-09,XOMA continues to expect cash usage for operating activities in the range of $55.0 million − $60.0 million in 2014.,0.11734285205602646,0.0129536809399724,0.8697034120559692,neutral,0.10438916832208633
16,2014-05-09,This includes license and contract-related revenues that the company expects to receive this year.,0.07293221354484558,0.005877222865819931,0.9211905598640442,neutral,0.06705498695373535
17,2014-05-09,XOMA currently carries a Zacks Rank #3 (Hold).,0.02088221162557602,0.020089400932192802,0.959028422832489,neutral,0.0007928106933832169
18,2014-05-09,"Some better-ranked stocks in the health care sector include Alexion Pharmaceuticals, Inc. ( ALXN ), ANI Pharmaceuticals, Inc. ( ANIP ) and Gilead Sciences Inc. ( GILD ).",0.6667048931121826,0.029769644141197205,0.303525447845459,positive,0.6369352340698242
19,2014-05-09,All these stocks carry a Zacks Rank #1 (Strong Buy).,0.5953417420387268,0.024893375113606453,0.3797648847103119,positive,0.5704483389854431
20,2014-05-09,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
21,2014-05-09,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
22,2014-05-09,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
23,2014-05-09,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
